Carregant...
A vicious partnership between AKT and PHLDA3 to facilitate neuroendocrine tumors
Pancreatic neuroendocrine tumors (PanNET) are rare cancers that generally have a poor prognosis. Accurate diagnosis and proper treatment of these tumors requires a better understanding of the molecular mechanisms underlying the development of PanNET. It has been shown that the mTOR inhibitor everoli...
Guardat en:
| Publicat a: | Cancer Sci |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5480075/ https://ncbi.nlm.nih.gov/pubmed/28295876 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13235 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|